BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Papageorgiou, Sotirios G.; Kontos, Christos K.; Foukas, Periklis; Panopoulou, Eleni; Vasilatou, Diamantina; Rapti, Stamatia-Maria; Gkontopoulos, Konstantinos; Bazani, Efthymia; Panayiotides, Ioannis G.; Dimitriadis, George; Scorilas, Andreas; Pappa, Vasiliki

doi:10.3109/10428194.2015.1126588

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The family of KLKs constitutes such a prominent example (28,29), as particular splice variants of the KLK1-KLK15 genes have been highlighted as putative biomarkers in human malignancies (30)(31)(32)(33)(34)(35). Very recently, ASDT has been used to partially reveal novel transcripts of tissue kallikrein (KLK1) (36) and several other members of the kallikrein-related peptidase (KLK) family (36)(37)(38)(39), as well as splice variants of the BCL2L12 gene (40,41), a prominent member of the apoptosis-related BCL2 family (42,43) with important prognostic value both in regard with solid tumors (44)(45)(46) as well as hematological malignancies (47,48), similarly to the major members of the BCL2 family, namely BCL2 and BAX (49)(50)(51). Moreover, the expression of a splice variant could be combined with clinical markers; for instance, the expression of BCL2L12 splice variant 1 and BCL2 variant alpha in malignant B cells of patients with chronic lymphocytic leukemia could be combined with lymphocyte count and/or other clinical features to provide a better prognostic system than the currently used ones (48,52).…”

Section: Biological and Clinical Significance Of Splice Variantsmentioning

confidence: 99%

Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis

Adamopoulos¹,

Theodoropoulou²,

Scorilas³

2018

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

Next-generation sequencing (NGS) can provide researchers with high impact information regarding alternative splice variants or transcript identifications. However, the enormous amount of data acquired from NGS platforms make the analysis of alternative splicing events hard to accomplish. For this reason, we designed the "Alternative Splicing Detection Tool" (ASDT), an algorithm that is capable of identifying alternative splicing events, including novel ones from high-throughput NGS data. ASDT is available as a PERL script at http://aias.biol.uoa.gr/~mtheo and can be executed on any system with PERL installed. In addition to the detection of annotated and novel alternative splicing events from high-throughput NGS data, ASDT can also analyze the intronic regions of genes, thus enabling the detection of novel cryptic exons residing in annotated introns, extensions of previously annotated exons, or even intron retentions. Consequently, ASDT demonstrates many innovative and unique features that can efficiently contribute to alternative splicing analysis of NGS data.

show abstract

Section: Biological and Clinical Significance Of Splice Variantsmentioning

confidence: 99%

Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis

Adamopoulos¹,

Theodoropoulou²,

Scorilas³

2018

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…), permitting their easy quantification paving the way for the development of non-invasive assays in the era of personalized medicine (84,85). Moreover, proteins that are targeted by important miRNAs could also participate in such multiparametric panels of biomarkers (86)(87)(88)(89), along with clinical markers (90)(91)(92). tRFs tRFs constitute novel sncRNA molecules generated by specific cleavage of tRNA transcripts.…”

Section: Introductionmentioning

confidence: 99%

Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer

Diamantopoulos¹,

Tsiakanikas²,

Scorilas³

2018

Ann. Transl. Med.

Self Cite

105

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) constitute a heterogeneous group of RNA molecules in terms of biogenesis, biological function as well as length and structure. These biological molecules have gained attention recently as a potentially crucial layer of tumor cell progression or regulation. ncRNAs are expressed in a broad spectrum of tumors, and they play an important role not only in maintaining but also in promoting cancer development and progression. Recent discoveries have revealed that ncRNAs may act as key signal transduction mediators in tumor signaling pathways by interacting with RNA or proteins. These results reinforce the hypothesis, that ncRNAs constitute therapeutic targets, and point out their clinical potential as stratification markers. The major purpose of this review is to mention the emergence of the importance of ncRNAs, as molecules which are correlated with cancer, and to discuss their clinical implicit as prognostic diagnostic indicators, biomarkers, and therapeutic targets.

show abstract

“…Recently, it has been shown that high BCL2L12 expression, assessed both at the mRNA level and via IHC, confers a more favorable outcome in patients with DLBCL, irrespective of COO and IPI. 127 Expression of other anti-apoptotic genes such as BIRC5 (survivin) and XIAP has been reported to confer an adverse effect on prognosis, 128,129 while results regarding CFLAR (c-FLIP) are contradictory. 130,131 On the other hand, the expression of CASP3 and CDKN1A , a downstream effector of TP53 , may correlate with favorable outcome.…”

Section: Other Biomarkersmentioning

confidence: 99%

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

Papageorgiou

Thomopoulos

Katagas

et al. 2021

Therapeutic Advances in Hematology

Self Cite

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment regimens over the last 20 years. In this context, prognostic biomarkers are of great importance in order to identify high-risk patients that might benefit from treatment intensification or the introduction of novel therapeutic agents. Herein, we review current knowledge on specific immunohistochemical or genetic biomarkers that might be useful in clinical practice. Gene-expression profiling is a tool of special consideration in this effort, as it has enriched our understanding of DLBCL biology and has allowed for the classification of DLBCL by cell-of-origin as well as by more elaborate molecular signatures based on distinct gene-expression profiles. These subgroups might outperform individual biomarkers in terms of prognostication; however, their use in clinical practice is still limited. Moreover, the underappreciated role of the tumor microenvironment in DLBCL prognosis is discussed in terms of prognostic gene-expression signatures, as well as in terms of individual biomarkers of prognostic significance. Finally, the efficacy of novel therapeutic agents for the treatment of DLBCL patients are discussed and an evidence-based therapeutic approach by specific genetic subgroup is suggested.

show abstract

BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Cited by 9 publications

References 15 publications

Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis

Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis

Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

Contact Info

Product

Resources

About